Navigation Links
Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
Date:4/16/2008

HAYWARD, Calif., April 16 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) presented preclinical data on its proprietary nuclear export inhibitors (NEI) showing potent in vitro and in vivo activity as well as tolerability in leukemia xenograft models, and further elucidating the NEI anticancer mechanism of action correlating inhibition of the target CRM1 with induction of apoptosis selectively in cancer cells compared to normal cells. Data on Kosan's NEIs were presented at the 2008 Annual Meeting of the American Association for Cancer Research (AACR), being held in San Diego, CA.

Kosan's NEIs are potent, specific inhibitors of CRM1, a highly conserved, essential protein that exports key regulatory proteins ("cargo" proteins) from the nucleus to the cytoplasm. Many cargo proteins that depend on CRM1 for nuclear export, such as p53, Bcr-Abl and FOXO-3a, function as tumor suppressors or transcription factors that protect normal cells by regulating cell growth and apoptosis (cell death). Accumulation of these CRM1 cargo proteins in the nucleus, by blocking nuclear export, leads to the inhibition of cell growth and apoptosis selectively in cancer cells. Kosan's polyketide-based NEI compounds have optimized pharmaceutical properties, including potency, durability of action and a wide therapeutic index.

"Kosan's NEI preclinical compounds continue to demonstrate attractive biological and pharmacological properties and potent anticancer activity and tolerability in both solid and liquid tumors," said Helen S. Kim, Kosan's President and Chief Executive Officer. "We are currently seeking a development partner for our NEI program, as we believe that the optimal strategy for continuing to explore the therapeutic ut
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 /PRNewswire-iReach/ -- Today E-T-A Circuit ... Appliance Inlet Module. The X3130, integrated with E-T-A,s ... a C14 appliance inlet module, rocker switch and ... three-in-one device allows design engineers to streamline the ... installation time by 66 percent - and reduce ...
(Date:6/18/2013)... HILL, N.C. , June 18, 2013  Recent ... more difficult for Medical Education groups at large pharmaceutical ... on the safe and effective use of their new ... the pharma industry, it is crucial that these ... reaching healthcare professionals. To address the changes ...
(Date:6/18/2013)... , June 18, 2013  Specialty Coating ... breakthrough in Parylene coating technologies: SCS microRESIST™ ... benefits of Parylene with antimicrobial properties to ... and components. (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ... (HAIs) increase and continue to pose a ...
Breaking Medicine Technology:Three-in-One X3130 Appliance Inlet Module 2Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2
... ViroPharma Incorporated (Nasdaq: VPHM ) today announced ... esterase inhibitor [human]) therapy at the 6th Annual C1 ... Food and Drug Administration in October 2008 for routine ... adolescents. In February 2009, ViroPharma was granted priority review ...
... 26 Ascenta Therapeutics announced today that eleven presentations ... an oral, pan-Bcl-2 inhibitor, in several major tumor types ... Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in ... www.asco.org .(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ...
Cached Medicine Technology:Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 2Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 3Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 4Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 5Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 6Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 7Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 3
(Date:6/19/2013)... Ore. A new understanding of the genetic process ... diagnosis of potentially dangerous lesions for some women, and ... anti-viral therapies in certain cases suggesting they could ... , The analysis provides a clearer picture of the ... human papillomavirus sometimes leads to chronic infection and, in ...
(Date:6/19/2013)... University of Iowa study reveals significant disparities between ... completing substance abuse treatment programs. Moreover, these disparities ... "Our findings suggest that for most states there,s ... of psychiatry and biostatistics. "There are strong racial ... to complete substance abuse treatment programs successfully, and ...
(Date:6/19/2013)... In early April, senior leaders from medical, law ... to discuss one question: how can first responders improve ... The preliminary results of this discussion are now available ... Hartford Consensus ," a concept paper published in the ... Trauma and Acute Care Surgery , official publication ...
(Date:6/19/2013)... -- Nearly 70 percent of Americans are ... than half take two, Mayo Clinic researchers say. ... prescribed, their study found. Twenty percent of patients ... to the findings, published online in the journal ... For audio and video of Dr. Jennifer St. ...
(Date:6/19/2013)... Effective Environmental Services and Clifford Woods, CEO, ... online links are devoted to a range of organic and ... Control Mold Magician and others. , Green products are easy ... the water as well as living plants. They contain beneficial ... accumulate at the bottom of a pond and render the ...
Breaking Medicine News(10 mins):Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Hartford consensus aims to improve survival after mass shootings 2Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:Effective Environmental Services Launch New Websites to Serve Customers 2
... becomes a job search engine with the functionality of a job board. ... ... the current economic woes, employment sites are experiencing an increase in the ... for new job openings, Fresho has changed its business concept from a ...
... Howard G. Smith,announces that a class action lawsuit has ... District of New Jersey against PharmaNet Development,Group, Inc. ("PharmaNet" ... behalf of all,persons who purchased or otherwise acquired the ... 2008. The complaint alleges that the Company,and certain of ...
... the,health insurance industry now have a dedicated community ... education coursework, and ensure best,practice application of research ... "We were looking for an ... there was no dedicated group for the health ...
... women need more culturally targeted information, study finds , , ... almost six times more likely than white women to ... breast cancer treatment, a new report says. , Researchers ... that despite being just as involved with their doctor ...
... Nov. 21 Album Creative Studios, Inc., a full-service brand ... for small businesses. , , ... services, and tailored them to small businesses with a very ... Creative , founded in 2002, combines experience and proven brand-building ...
... Health Science Center at Houston will launch a new ... geriatrics training for physicians through a prestigious $2 million ... million in matching funds., "This will allow us to ... junior medical student to practicing physicians. With the reach ...
Cached Medicine News:Health News:Fresho.com Adapts As The Online Recruiting Market Heats Up 2Health News:Law Offices of Howard G. Smith Announces Class Action Lawsuit on Behalf of Investors of PharmaNet Development Group, Inc. 2Health News:Society of Insurance Research and Fletcher/CSI Create First Forum for Research Professionals in the Health Insurance Industry 2Health News:Society of Insurance Research and Fletcher/CSI Create First Forum for Research Professionals in the Health Insurance Industry 3Health News:Album Creative Studios Tailors Big Brand Marketing For Small Businesses 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4
... the Flavavirus group pf viruses. This virus ... Dengue fever are the sudden onset of ... limbs, lymphadenopathy,maculopapular rash and retrobulbar pain.,This test ... aid in the diagnosis of anti-Dengue IgM ...
... The Dengue virus belongs to the Flavavirus ... commonly throughout the tropics.,Symptoms of Dengue fever ... pain in the back and limbs, lymphadenopathy,maculopapular ... for professional use as an aid in ...
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance....
For the rapid determination of human chorionic gonadotropin (hCG) in urine. The test strip is used to obtain a visual qualitative result....
Medicine Products: